R238
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 104
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.540
- IL6_JAK_STAT3_SIGNALING+0.480
- ALLOGRAFT_REJECTION+0.450
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_DN+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- COMPLEMENT+0.300
- XENOBIOTIC_METABOLISM+0.250
- TNFA_SIGNALING_VIA_NFKB+0.230
Top 10 suppressed
- TGF_BETA_SIGNALING-0.470
- ANGIOGENESIS-0.450
- MYC_TARGETS_V1-0.450
- WNT_BETA_CATENIN_SIGNALING-0.450
- HEDGEHOG_SIGNALING-0.430
- PROTEIN_SECRETION-0.430
- UV_RESPONSE_DN-0.400
- G2M_CHECKPOINT-0.370
- E2F_TARGETS-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290925 | — | — | 0.873 |
| 2 | TCGA-S3-AA17-01A-11R-A41B-07 | — | D | 0.865 |
| 3 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.857 |
| 4 | TCGA-AC-A5XS-01A-11R-A29R-07 | — | B | 0.849 |
| 5 | R49 | — | — | 0.849 |
| 6 | SRR2778078 | — | — | 0.839 |
| 7 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.838 |
| 8 | SRR25617853 | — | D | 0.823 |
| 9 | aeac6db7-09bd-45f9-a5fd-c8358f86bff8 | — | — | 0.817 |
| 10 | TCGA-GD-A76B-01A-11R-A32O-07 | — | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |